Clinical trial / 2016
In patients with NAFLD, 12 weeks of ginger supplementation significantly reduced ALT, GGT, inflammatory cytokines, insulin resistance, and hepatic steatosis.
A randomized, double-blind, placebo-controlled pilot trial assigned 44 patients with NAFLD to receive either 2 grams per day of a ginger supplement or an identical placebo for 12 weeks, with both groups advised to follow a modified diet and physical activity program. Compared to placebo, ginger supplementation led to significant reductions in alanine aminotransferase, γ-glutamyl transferase, inflammatory cytokines, insulin resistance index, and hepatic steatosis grade. No significant effect was found on hepatic fibrosis or aspartate aminotransferase.
- Study type
- Randomized, double-blind, placebo-controlled clinical trial
- Who was studied
- 44 patients with NAFLD
- What was measured
- Metabolic parameters and indicators of liver damage (including ALT, GGT, inflammatory cytokines, insulin resistance index, hepatic steatosis grade, fibrosis, and AST)
THE PAPER
Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Hepat Mon, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.